Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Advancement of the implementation of evidence-based therapies for cardiovascular-kidney-metabolic conditions: A multi-stakeholder perspective

American Heart Journal(2025)10.1016/j.ahj.2025.03.005Source: DataRank Database

Advancement of the implementation of evidence-based therapies for cardiovascular-kidney-metabolic conditions: A multi-stakeholder perspective is a research paper published in American Heart Journal (2025). On theSindex it has a DataRank of 0.165. It has been cited 2 times.

N/A

0.165DataRank · unranked

Scored on demand from live citation data

Open Access2 citations

Free full text

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (13 grants)Impact (FWCI 2.95)OA: greenTopics (26)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 100%Citation Network 0%

Base Score Contribution

0.165

From this paper's citation signal

Citation Network Contribution

Citation network not refreshed for this result

This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.

Learn more about DataRank methodology →

Authors (20)

Harriette Van Spall,Hayden B. Bosworth ORCID,Konstantin A. Krychtiuk ORCID,John A. Spertus ORCID,Samuel Fatoba

Live enrichment

PubMed:40107643 OpenAlex:https://openalex.org/W4408521600

NIDDK NIH HHS

Grant: U24 DK114886

NIDDK NIH HHS

Grant: U2C DK114886

NCATS NIH HHS

Grant: UL1 TR002319

NIDDK NIH HHS

Grant: U54 DK083912

NIDDK NIH HHS

Grant: U01 DK100846

NHLBI NIH HHS

Grant: OT2 HL161847

NHLBI NIH HHS

Grant: T32 HL069749

NIH HHS

Grant: OT2 OD032581

HSRD VA

Grant: IK6 HX003161

NIMHD NIH HHS

Grant: R01 MD014712

Boehringer Ingelheim Corp USA

Novo Nordisk AS

Bayer US

FWCI

2.95

Citation Percentile

0.9%

Citation Trend

2025

greenLicense: https://doi.org/10.15223/policy-004

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC12908198/

publisherhttps://api.elsevier.com/content/article/PII:S0002870325000845?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0002870325000845?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.ahj.2025.03.005

Fields of Study

Health Systems, Economic Evaluations, Quality of LifeBlood Pressure and Hypertension StudiesMeta-analysis and systematic reviewsMedicineEconomicsHumansCardiovascular DiseasesEvidence-Based MedicineUnited StatesImplementation ScienceStakeholder ParticipationMetabolic Diseases

MeSH Terms

Stakeholder ParticipationImplementation ScienceCardiovascular DiseasesHumansMetabolic DiseasesUnited StatesEvidence-Based Medicine

Keywords

MedicinePerspective (graphical)Intensive care medicineStakeholderKidneyInternal medicinePublic relations

Sustainable Development Goals

SDG 0: Good health and well-being